Evidence map›Paper›PMID 25320311›Full record

ArticleJournal of virology2015

The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.

Daniela Weiskopf, Michael A Angelo, Derek J Bangs, John Sidney, Sinu Paul, Bjoern Peters, Aruna D de Silva, Janet C Lindow, Sean A Diehl, Stephen Whitehead and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 167 citations in OpenAlex.

  1. Trial
  2. Safety and Immunogenicity of an AS03The American journal of tropical medicine and hygiene · 2020
    Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge.The American journal of tropical medicine and hygiene · 2016
    Trial
  8. Dengue virus infection.Nature reviews. Disease primers · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. T Cell Responses During Dengue Infection.Current topics in microbiology and immunology · 2026
    Review
  17. Review
  18. Article
  19. Dengue Vaccines.Current topics in microbiology and immunology · 2026
    Review
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Daniela WeiskopfDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA daniela@liai.org.
Michael A AngeloDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Derek J BangsDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
John SidneyDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Sinu PaulDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Bjoern PetersDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Aruna D de SilvaDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA Genetech Research Institute, Colombo, Sri Lanka.
Janet C LindowUniversity of Vermont College of Medicine and Vaccine Testing Center, Burlington, Vermont, USA.
Sean A DiehlUniversity of Vermont College of Medicine and Vaccine Testing Center, Burlington, Vermont, USA.
Stephen WhiteheadNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Anna DurbinJohns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Beth KirkpatrickUniversity of Vermont College of Medicine and Vaccine Testing Center, Burlington, Vermont, USA.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
La Jolla Institute for Immunology · USUniversity of Vermont · USJohns Hopkins University · USNational Institutes of Health · US

Funding

Clinical Trials of Biodefense Vaccines (Dengue, West Nile Virus, TBEV)ZIAAI000987 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WHITEHEAD, STEPHEN · 2009 to 2025
$37.9M
Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
FIC NIH HHS D43 TW010540Intramural NIH HHSNIAID NIH HHS HHSN272200900042CPHS HHS HHSN27220140045C
6 · The paper itself

Abstract

unlabelledThe incidence of infection with any of the four dengue virus serotypes (DENV1 to -4) has increased dramatically in the last few decades, and the lack of a treatment or vaccine has contributed to significant morbidity and mortality worldwide. A recent comprehensive analysis of the human T cell response against wild-type DENV suggested an human lymphocyte antigen (HLA)-linked protective role for CD8(+) T cells. We have collected one-unit blood donations from study participants receiving the monovalent or tetravalent live attenuated DENV vaccine (DLAV), developed by the U.S. National Institutes of Health. Peripheral blood mononuclear cells from these donors were screened in gamma interferon enzyme-linked immunosorbent spot assays with pools of predicted, HLA-matched, class I binding peptides covering the entire DENV proteome. Here, we characterize for the first time CD8(+) T cell responses after live attenuated dengue vaccination and show that CD8(+) T cell responses in vaccinees were readily detectable and comparable to natural dengue infection. Interestingly, whereas broad responses to structural and nonstructural (NS) proteins were observed after monovalent vaccination, T cell responses following tetravalent vaccination were, dramatically, focused toward the highly conserved NS proteins. Epitopes were highly conserved in a vast variety of field isolates and able to elicit multifunctional T cell responses. Detailed knowledge of the T cell response will contribute to the identification of robust correlates of protection in natural immunity and following vaccination against DENV. IMPORTANCE: The development of effective vaccination strategies against dengue virus (DENV) infection and clinically significant disease is a task of high global public health value and significance, while also being a challenge of significant complexity. A recent efficacy trial of the most advanced dengue vaccine candidate, demonstrated only partial protection against all four DENV serotypes, despite three subsequent immunizations and detection of measurable neutralizing antibodies to each serotype in most subjects. These results challenge the hypothesis that seroconversion is the only reliable correlate of protection. Here, we show that CD8(+) T cell responses in vaccinees were readily detectable and comparable to natural dengue virus infection. Detailed knowledge of the T cell response may further contribute to the identification of robust correlates of protection in natural immunity and vaccination against DENV.

Indexed as

AdolescentAdultAntigens, ViralCD8-Positive T-LymphocytesDengue VaccinesDengue VirusEnzyme-Linked Immunospot AssayEpitopesFemaleHumansInterferon-gammaMaleMiddle AgedNational Institutes of Health (U.S.)United StatesVaccines, AttenuatedAntigens, ViralDengue VaccinesEpitopesInterferon-gammaVaccines, Attenuated

Identifiers

PMID25320311
PMCPMC4301095
OpenAlexW2151742317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.